Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
blood eosinophil count, COPD, diagnostic test, doctor's questionnaire, Lung specialist
Brief summary
This study will evaluate the diagnostic measures (including blood eosinophil counts) commonly used by lung specialist's in routine clinical care of subjects with COPD in Germany and how these diagnostic tests influence the physician's treatment decisions. The study will be conducted in three parts. In the first part, lung specialist's, who will not participate in the survey, will develop doctor's questionnaire. The second part is an interventional cross-sectional study, wherein approximately 30 lung specialists will be enrolled and data on their perspective on diagnosis and treatment of COPD subjects will be collected via the revised doctor's questionnaire. The third part is a retrospective non-interventional study where each doctor will collect retrospective data from selected subjects with COPD from the time of informed consent up to 12 months before. The retrospective data will be collected from subject files of approximately 250 subjects with COPD.
Interventions
OTHERDoctor's questionnaire
The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
OTHERSubject file
All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
Sponsors
Institut Dr. Schauerte (IDS)
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
35 Years to No maximum
Inclusion criteria
For participating centers (Sample 1: 30 lung specialists from Germany) * More than 10 years of experience in respiratory medicine * At least 500 subjects under supervision in hospital- or office-based setting: a) Focus on obstructive lung diseases. b) Board certification. c) Informed consent to participate in this study and to share files of consenting subjects. For subjects (Sample 2: 250 COPD subjects from these 30 doctors from sample 1) * Written informed consent to use his/her data. * Age \>=40 years * Pack years \>10, current or former smoking * Duration of COPD: \>=1 year since COPD diagnosis record in subject files (also confirmed by spirometry) * No concurrent asthma diagnosis * At least one year of documented disease history at participating study doctors and have to be under the care of the before mentioned physician during this time because of COPD.
Exclusion criteria
* Subjects who are pregnant and breastfeeding (in the last 12 months) * Subjects currently participating in any interventional study * Subjects with severe comorbidities which would have influence on the COPD therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of physicians with usage of diagnostic tests in routine clinical practice | Up to 12 months | The data on diagnostic test including blood eosinophil count commonly used by lung specialists in routine clinical practice will be obtained from doctor's questionnaire. |
| Number of physician reported rationale for choice of diagnostic test | Up to 12 months | The reasons for choice of diagnostic test will be determined from doctor's questionnaires and from medical chart review. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with use of other diagnostic measures | Up to 12 months | Number of subjects with use of other diagnostic measures such as spirometry, X-ray, thoracic computer tomography and specific blood tests will be analyzed using data from subject files. |
| Number of subjects with use of patient reported outcome (PRO) assessment | Up to 12 months | Number of subjects with use of questionnaires like COPD assessment test (CAT) and dyspnea assessment will be analyzed using data from subject files. |
| Number of subjects with a history of respiratory medication | Up to 12 months | Number of subjects with a history of respiratory medication will be analyzed using data from subject files. |
| Number of subjects receiving current medication | Up to 12 months | Number of subjects receiving current medication will be analyzed using data from subject files. |
| Number of subjects receiving COPD maintenance treatment | Up to 12 months | Number of subjects receiving COPD maintenance treatment will be analyzed using data from subject files. |
| Number of subjects receiving immunosuppressive treatment | Up to 12 months | Number of subjects receiving immunosuppressive treatment will be analyzed using data from subject files. |
| Number of subjects receiving allergic treatment | Up to 12 months | Number of subjects receiving allergic treatment will be analyzed using data from subject files. |
| Number of physician reported reasons for blood eosinophil test selection | Up to 12 months | The reasons blood eosinophil test selection will be analyzed using data from doctor's questionnaires. |
| Number of subjects with use of antibiotics | Up to 12 months | Number of subjects with use of antibiotics will be analyzed using data from subject files. |
| Number of subjects receiving any COPD medication | Up to 12 months | Number of subjects receiving any COPD medication will be analyzed using data from subject files. |
| Number of subjects with history of exacerbations | Up to 12 months | Number of subjects with history of exacerbations will be analyzed using data from subject files. |
| Number of subjects with hospitalization for COPD | Up to 12 months | Number of subjects with hospitalization for COPD will be analyzed using data from subject files. |
| Number of subjects with emergency room visits related to COPD | Up to 12 months | Number of subjects with emergency room visits related to COPD will be analyzed using data from subject files. |
| Number of subjects with concomitant diseases | Up to 12 months | Number of subjects with concomitant diseases will be analyzed using data from subject files. |
| Number of subjects receiving oral corticosteroids (OCS) for exacerbations | Up to 12 months | Number of subjects with maintenance and rescue use of OCS for exacerbations will be analyzed using data from subject files. |
| Number of physician reported reasons for drug selection | Up to 12 months | The selection of drugs by lung specialists for subjects with COPD will be analyzed using information obtained from medical chart review. |
Countries
Germany
Outcome results
None listed